Information de reference pour ce titreAccession Number: | 00006454-200301000-00006.
|
Author: | FIREMAN, BRUCE MA; BLACK, STEVEN B. MD; SHINEFIELD, HENRY R. MD; LEE, JANELLE DRPH; LEWIS, EDWIN MPH; RAY, PAULA MPH
|
Institution: | From the Kaiser Permanente Division of Research and the Kaiser Permanente Vaccine Studies Center, Oakland, CA.
|
Title: | |
Source: | Pediatric Infectious Disease Journal. 22(1):10-16, January 2003.
|
Abstract: | Context. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for infants to protect against invasive disease, but its impact on otitis might also have public health importance.
Objective. To examine the impact of PCV on the incidence of otitis media, frequent otitis media and tympanostomy tube procedures and to assess whether the effectiveness of the vaccine wanes after age 24 months and varies by race, sex or season.
Design, setting and patients.. From 1995 to 1998, 37 868 children at Kaiser Permanente in Northern California were randomized to receive PCV or a control vaccine in a double blind trial and were followed through April 1999.
Interventions. Children received a primary series at 2, 4 and 6 months of age and a booster at 12 to 15 months.
Main outcome measures. Visits for otitis, frequent visits for otitis and tympanostomy tube procedures. Otitis was ascertained from diagnosis checklists routinely marked by physicians.
Results. Control children averaged 1.8 otitis visits per year. Children given PCV had fewer otitis visits than control children in every age group, sex, race and season examined. Intention-to-treat analysis permitted rejection of the null hypothesis that PCV is ineffective against otitis media (P < 0.0001). In children who completed the primary series per protocol, PCV reduced otitis visits by 7.8% [95% confidence interval (CI), 5.4 to 10.2%] and antibiotic prescriptions by 5.7% (CI 4.2 to 7.2%). Frequent otitis was reduced by amounts that increased with otitis frequency, from a 10% reduction in the risk of 3 visits to a 26% reduction in the risk of 10 visits within a 6-month period. Tube placements were reduced by 24% (CI 12 to 35%).
Conclusion. In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.
(C) 2003 Lippincott Williams & Wilkins, Inc.
|
Author Keywords: | Pneumococcal vaccine; otitis media; Streptocccus pneumonia; randomized clinical trials.
|
References: | 1. Berman S. Otitis media in children. N Engl J Med 1995; 335: 1560-5.
2. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160: 83-94.
3. Fried VM, Makuc DM, Rooks RN. Ambulatory health care visits by children: principal diagnosis and place of visit. Vital and health statistics. Series 13, No. 137. DHHS Publication (PHS) 98-1798. Washington, DC: Government Printing Office, 1998.
4. Schappert SM. Office visits for otitis media: United States 1975-90: advance data from vital and health statistics. Hyattsville: National Center for Health Statistics, 1992:214:1-19.
5. American Academy of Pediatrics. Committee on Infectious Diseases Policy statement. Pediatrics 2000; 106: 362-6.
6. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49 (RR-9):1-35.
7. Pelton PI. Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis J 1998; 17: 540-3.
8. Bluestone CD, Klein JO. Otitis media in infants and children. 2nd ed. Philadelphia: Saunders, 1995.
9. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9.
10. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95.
11. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283: 1460-88.
12. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992; 92: 703-10.
13. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999; 18: 757-63.
14. Andersen PK, Gill RD. Cox's regression model counting process: a large sample study. Ann Stat 1982; 10: 1100-20.
15. Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc 1989; 84: 1074-8.
16. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348: 272.
17. Dagan R, Fraser D. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr Infect Dis J 2000; 19 (Suppl): S79-88.
18. CDC. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage: Advisory Committee on Immunization Practices. MMWR 2001; 50: 1140-2.
19. Pichichero ME, Pode MD. Assessing diagnostic accuracy and tympanocentesis skills in the management of otitis media. Arch Pediatr Adolesc Med 2001; 155: 1137-42.
20. Pelton SI, Klein JO. The promise of immunoprophylaxis for prevention of acute otitis media. Pediatr Infect Dis J 1999; 18: 926-35.
21. Infante-Rivard C, Fernandez A. Otitis media in children: frequency, risk factors, and research avenues. Epidemiol Rev 1993; 15: 444-65.
22. Pukander J, Luotonen J, Sipila M, et al. Incidence of acute otitis media. Acta Otolaryngol 1982; 93: 447-53.
23. Sipila M, Pulander J., Karma P. Incidence of acute otitis media up to the age of 11/2 years in urban infants. Acta Otolaryngol 1987; 104: 138-45.
24. Lanphear BP, Byrd RS, Auinger P, Hall CB. Increasing prevalence of recurrent otitis media among children in the United States. Pediatrics 1997; 99: E1.
25. Teale DW, Klein JO, Chase C, et al. Otitis media in infancy and intellectual ability, school achievement, speech, and language at age 7 years: Greater Boston Otitis Media Study Group. J Infet Dis 1990; 162: 685-94.
26. Paradise JL, Haggard MP, Lous J, et al. Developmental implications of early-life otitis media. Int J Pediatr Otohinolaryngol 1995; 32 (Suppl): S37-44.
27. Scrag SJ, Beall B, Dowell S. Resistant pneumococcal infections: the burden of disease and challenges in monitoring and controlling antimicrobial resistance. World Health Organization. WHO/CDS/CSR/DRS/20016:1-30.
28. Giebink GS. The prevention of pneumococcal disease in children. N Engl J Med 2001; 345: 1177-83.
|
Language: | English.
|
Document Type: | Original Studies.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0891-3668
|
NLM Journal Code: | oxj, 8701858
|
Annotation(s) | |
|
|